Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.46 |
| ▸ | BMP1 | P13497 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173081 | 0.83 | GLP1R (0.47) | GLO1PTGS1GSTK1BMP1GLP1R | |
| SCHEMBL21360278 | 0.83 | FOLH1 (0.58) | FOLH1RIMKLANAALAD2GNPATNOD1 | |
| SCHEMBL30148833 | 0.82 | PTGS1 (0.59) | GLO1PTGS1GSTK1BMP1FOLH1 | |
| SCHEMBL28927466 | 0.82 | PTGS1 (0.59) | GLO1PTGS1GSTK1BMP1FOLH1 | |
| SCHEMBL6809578 | 0.80 | NOD1 (0.58) | GLO1NOD1GLP1RFAAH | |
| SCHEMBL27935271 | 0.80 | NOD1 (0.58) | GLO1NOD1GLP1RFAAH | |
| SCHEMBL24235568 | 0.80 | FOLH1 (0.58) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL173084 | 0.79 | ALDH1A1 (0.44) | GLO1PTGS1GSTK1BMP1FOLH1 | |
| SCHEMBL2804509 | 0.77 | PTGS1 (0.51) | GLO1PTGS1GSTK1BMP1FOLH1 | |
| SCHEMBL29050824 | 0.77 | PTGS1 (0.51) | GLO1PTGS1GSTK1BMP1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | MAX PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058932-A1 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION | VIP, FIBP, MMP7 | GLO1 2485/4885PTGS1 1350/4885GSTK1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.